TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sonographic Monitoring of Weaning of Cerebrospinal Fluid Drainages

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent of patient or relative and statement of independent physician~* Patient treated with EVD or LD undergoing clamping of EVD/LD~* Age ≥18 ≤ 80 years~Exclusion Criteria~* Pregnancy and breastfeeding~* Acute coronary syndromes, severe ischemic heart disease (requiring revascularisation), severe aortic and mitral valve disease, severe congestive heart failure (NYHA \>III/IV)~* Severe pulmonary or renal dysfunction~* Known allergy or adverse reaction to contrast material

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- All study participants (Type: None): The study population consists of consecutive patients undergoing clamping of EVD/LD treated at the Departments of Neurosurgery or Intensive Care Medicine at the University Hospital Bern

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Steroids and Control of Severe Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Severe persistent asthma bronchiale with diagnosis according to the criteria of the Global Initiative for Asthma (GINA) executive summary~* Treatment with at least inhaled corticosteroids (ICS) and long acting b agonists (LABA)~* Evidence of inflammatory triggered form of asthma with at least one of the following:~* sensitization to typical aerogenous allergens~* increased Serum IgE levels~* Eosinophilia in peripheral blood~* Proven Eosinophilia in sputum differential (\> 3%) in the previous 2 years~* at least 2 exacerbations of asthma within the previous 24 months leading to unscheduled presentation at a health care provider and/or systemic corticosteroid~* Signed informed consent~* Requirements of the local ethics committee are met~Exclusion Criteria:~* Acute exacerbation of asthma within the last 6 weeks Rtot \> 350% predicted capillary pO2 \< 60mmHG, pCo2 \> 50mmHG near fatal asthma or anaphylaxis in history~* Age ≤ 18 and \> 80 years~* Active smoking or \> 15 pack-years former smoking~* Oral steroid treatment with a prednisolon-equivalent dose exceeding 10 mg per day~* Pregnancy, nursing females~* Female without use of effective contraceptive method~* Treatment with investigational drugs over the past 30 days or during the course of the trial~* Severe and uncontrolled gastroesophageal reflux disease~* Ongoing psychiatric disorder~* Treatment with systemic corticosteroids for any reason other than asthma~* Other active lung diseases~* Medical history of other uncontrolled diseases 3 months prior randomization (e.g. infections, coronary heart diseases and metabolic diseases)~* Any history of malignancy requiring ongoing treatment and/or limiting life-expectancy~* Clinically significant abnormalities in electrocardiogram (ECG) or laboratory exams~* Asthma related to non-steroidal anti-inflammatory drug (NSAID)~* Insulin dependent diabetes mellitus~* Cataract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Eligible patients need:~* to be on treatment dose (1mg/kg twice daily or 1.5mg/kg daily) enoxaparin at the time of presentation for elective surgery~* and must be able to accurately report the timing of their last dose and the administered dosage.~* Patients must also be between the ages of 18-100 years of age~* and must be able to give written consent to participate.~Exclusion Criteria:~* Patients with severe renal insufficiency (creatinine clearance \<30ml/min) will be excluded from the study, as the elimination of enoxaparin is known to be affected in this patient population.~* Pregnant patients will also be excluded, as the elimination and metabolism of enoxaparin is known to be altered in this patient population, and dose adjustments are recommended if treatment dose enoxaparin is used during pregnancy.~* Patients who are receiving enoxaparin as a bridge from another anti-Xa inhibiting medication will be excluded as this could unpredictably affect the results of anti-Xa testing. These medications include: Apixaban, Edoxaban, Fondaparinux, and Xarelto.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- 24 Hours group (Type: ACTIVE_COMPARATOR): Group one will be instructed to administer their last dose of enoxaparin at 07:00 in the morning on the day prior to their scheduled surgery date. This will mean that patients who have their surgery scheduled for 07:00 the following day will be 24-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, however this is currently considered normal clinical practice.
- 36 Hours Group (Type: EXPERIMENTAL): Group 2 will be instructed to administer their last dose of enoxaparin at 19:00 in the evening two days prior to their scheduled surgery date. Patients presenting for surgery at 07:00 two days later will be 36-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, but again this mimics normal clinical practice in which the timing of the last dose of self-administered enoxaparin is not routinely adjusted based on the scheduled surgical start time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-INCLUSION:~18 years of age or older Have received prior chemotherapy for histologically proven advanced non-small cell lung cancer, up to 3 prior treatments Tumors display high ISG15 (ISG15H) at screening Life expectancy of at least 12 weeks ECOG/Zubrod performance status of 0-2 Provide informed consent permission to participate~Adequate bone marrow function as follows:~1. Absolute neutrophil count of greater than or equal to 1,500 or cells/mm3, and 2) Platelet count greater than or equal to 100,000/mm3 and 3) Absence of a regular red blood cell transfusion requirement~Adequate hepatic function with:~1. Total bilirubin less than or equal to 4.0 mg/dl, and~2. SGOT or SGPT less than or equal to four times ULN~Adequate renal function as defined by:~1) Serum creatinine less than or equal to 1.5 x ULN~Exclusion Criteria:~Symptomatic brain metastases~Pregnant women or nursing mothers~Patients of child bearing potential must use adequate contraception.~May not be receiving other concurrent chemotherapy or radiation therapy~Severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections~Previous hypersensitivity reaction to camptothecins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Irinotecan (Type: EXPERIMENTAL): The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. SAD Stage~   * RA diagnosed according to the ACR~  * For patients taking anti-rheumatic therapies, receipt of a stable regimen prior to randomization~  * Previous treatment with biologic agents, including anti-TNF agents, permitted but discontinued for an appropriate washout period~2. MAD Stage (same as above with the addition of the following)~   * Failure of at least one biologic agent, defined as lack of or loss of response or intolerance~  * Active disease defined by swollen and tender count~Exclusion Criteria:~* Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty's syndrome~* Malignancy, or prior malignancy, other than non-melanoma skin cancer or cervical carcinoma in situ that has been resected~* History of treatment with any T cell-directed therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Activation Timing and Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* any patient followed at Essentia Health - St. Mary's Medical Center, Duluth, MN and who is referred for a diagnostic EP study with or without ablation.~Exclusion Criteria:~* any patient who will undergo an EP study without usual placement of a coronary sinus catheter;~* any patient with permanent (chronic) atrial fibrillation or tachycardia who will not undergo restoration of sinus rhythm during the course of the procedure as a usual part of the procedure;~* any patient who is not willing or unable to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atrial Fibrillation (Type: None): Patients with atrial fibrillation during the EP study
- Bundle Branch Block (Type: None): Patient with bundle branch block during the course of the EP study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CPSP or TGN/facial pain refractory to other medical treatments~* Pain \> 1 year prior to baseline~* Pain intensity with an average daily VAS score \> 5 demonstrated by 12 ratings across 4 days~* Stable pain medication for \> 1 month prior to baseline~Exclusion Criteria:~* CPSP with important paresis/severe motor deficit in the area of pain~* TGN/facial pain with complete deafferentation pain~* Atypical facial pain, i.e. when objective evidence for neuropathic facial pain syndromes is lacking and when specific psychological and behavioral factors can be identified~* Pain associated with malignant neoplastic disease anywhere in the body or head~* History of epilepsy~* Presence of a deterioration of cognitive functions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female over 50 years of age~2. One, two, or three segment degenerative lumbar spinal stenosis (DLSS)~3. Symptoms of radiographically confirmed DLSS like leg, buttock, or groin pain with or without back pain and absence of a peripheral motoric deficit~4. Pain relief in inclination or sitting~5. Ability to walk over a distance of 50 m~6. Unsuccessful conservative therapy for 3 months under outpatient conditions~7. Informed consent~Exclusion Criteria:~1. Fixed motoric deficit~2. Cauda equina syndrome~3. Previous surgery of the lumbar spine~4. Severe osteoporosis of the vertebrae and/or of the hip~5. Spondylolisthesis more severe than Meyerding I (on scale of I-IV)~6. Metastasis of the vertebrae~7. Mentally disabled persons

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Spacer (Type: EXPERIMENTAL): Implantation of a percutaneously implanted interspinous device (spacer)
- physiotherapy (Type: OTHER): The control group will receive at least physiotherapy and physical therapy (e.g. massage and fango). Under inpatient conditions therapy will last for seven days. After discharge physical therapy has to be continued for 5 weeks. A schedule will ensure the consistency of the physical therapy. The inpatient-treatment can be repeated every 6 months if necessary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single Ascending Dose Study of PBI-4547 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male participants or non-childbearing potential female participants, ≥18 and ≤55 years.~* Body mass index \> 18.5 and \< 30.0 kg/m\^2, and body weight ≥ 50.0 kg for male participants and ≥ 45.0 kg for female participants.~* Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to screening.~* Male participants with a pregnant partner must agree to use a condom from the first dosing until at least 90 days after study drug administration.~* Male participants must be willing not to donate sperm until 90 days after study drug administration.~Exclusion Criteria:~* Any clinically significant abnormality or abnormal laboratory test results.~* An estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m\^2.~* Positive urine drug screen and history of significant drug abuse.~* History of significant allergic reactions to any drug.~* Use of any drugs known to induce or inhibit hepatic drug metabolism.~* Positive pregnancy test or breast-feeding participant.~* Clinically significant abnormalities in ECG, blood pressure, and heart rate at screening.~* History of significant alcohol abuse or regular use of alcohol.~* Use of medication other than topical products without significant systemic absorption.~* Donation of plasma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1, Dose 1 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 1 of PBI-4547 or matching Placebo tablets by mouth
- Cohort 2, Dose 2 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 2 of PBI-4547 or matching Placebo tablets by mouth
- Cohort 3, Dose 3 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 3 of PBI-4547 or matching Placebo tablets by mouth
- Cohort 4, Dose 4 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 4 of PBI-4547 or matching Placebo tablets by mouth
- Cohort 5, Dose 5 of PBI-4547 or Placebo (Type: EXPERIMENTAL): Dose 5 of PBI-4547 or matching Placebo tablets by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Deep Brain Stimulation Effects Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is indicated for Activa® DBS implant for the treatment of Parkinson's disease and scheduled for surgery at the study site.~* Subject is willing to sign the informed consent to participate in the study.~* Subject is 18 years of age or older.~* Subject is a male or non-pregnant female.~* Subject has no factors that would put the subject at an additional risk for intra-operative or postoperative bleeding. This includes underlying disorders of the coagulation cascade (eg, hemophilia), disorders that affect platelet count or function (eg, Von Willebrand's disease), as well as administration of any anti-platelet or anti-coagulant medication in the 7 days prior to surgery, or any history of anticoagulant or aspirin use, that in the view of the neurosurgeon or neurologist would place the subject at an increased risk for intra-operative or postoperative bleeding.~Exclusion Criteria:~* Subject is indicated for DBS for treating a disorder other than Parkinson's disease.~* Subject has any medical contraindications to undergoing DBS surgery, (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery).~* Subject has a history of hemorrhagic stroke.~* Subject has a history of a neurosurgical ablation procedure.~* Subject is currently enrolled in or plans to enroll in any concurrent study that may confound the results of this study, as determined by the investigator or Medtronic.~* Subject has a diagnosis of acute myocardial infarction or cardiac arrest less than or equal to 6 months prior to the screening testing.~* Subject has a history of a seizure disorder~* Subject requires short surgery time due to general health issues, as determined by the investigator.~* Subject is a woman who is pregnant or planning to become pregnant, or a woman of child-bearing potential, who is not using a medically-acceptable method of birth control. Women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to the investigational procedure visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study device arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years of age~* Patients with a limited SCLC demonstrated histologically responsive or stable to radiochemotherapy or patients with a histologically proven extended SCLC responding to chemotherapy.~* WHO Performance Index 0-1 and / or Karnovsky Index\> 70~* Possibility of long-term monitoring~Exclusion Criteria:~* Concomitant chemotherapy~* Impossibility of performing an MRI or CT without injection~* Presence of cerebral metastases~* History of cerebral irradiation at any time~* Patient suffering from severe collagenosis~* Patient with cognitive disorders with MMSE score \<24

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Irradiation prophyllactique cérébrale (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Protocol to Wean From Noninvasive Mechanical Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. noninvasive mechanical ventilation \> 24 hours.~2. age \>18 years~Exclusion Criteria:~1. severe cerebraI，heart，hepatic and renal faiIure.~2. facial or cranial trauma or surgery.~3. facial abnormalities.~4. recent gastric or esophageal surgery.~5. active upper gastrointestinal bleeding.~6. large amount of sputum with weak cough ability~7. lack of co-operation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- protocol group (Type: ACTIVE_COMPARATOR): This group patients are weaned as the protocol which the investigators described.
- clinicians' order group (Type: OTHER): This group patients are weaned as the clinicians' order.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues